These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

494 related items for PubMed ID: 19214942

  • 1. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes.
    Holstein A, Hahn M, Stumvoll M, Kovacs P.
    Horm Metab Res; 2009 May; 41(5):387-90. PubMed ID: 19214942
    [Abstract] [Full Text] [Related]

  • 2. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas.
    Javorsky M, Klimcakova L, Schroner Z, Zidzik J, Babjakova E, Fabianova M, Kozarova M, Tkacova R, Salagovic J, Tkac I.
    Eur J Intern Med; 2012 Apr; 23(3):245-9. PubMed ID: 22385882
    [Abstract] [Full Text] [Related]

  • 3. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.
    Sesti G, Laratta E, Cardellini M, Andreozzi F, Del Guerra S, Irace C, Gnasso A, Grupillo M, Lauro R, Hribal ML, Perticone F, Marchetti P.
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2334-9. PubMed ID: 16595597
    [Abstract] [Full Text] [Related]

  • 4. Genetic study of Saudi diabetes (GSSD): significant association of the KCNJ11 E23K polymorphism with type 2 diabetes.
    Alsmadi O, Al-Rubeaan K, Wakil SM, Imtiaz F, Mohamed G, Al-Saud H, Al-Saud NA, Aldaghri N, Mohammad S, Meyer BF.
    Diabetes Metab Res Rev; 2008 Feb; 24(2):137-40. PubMed ID: 17922473
    [Abstract] [Full Text] [Related]

  • 5. Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients.
    Ragia G, Tavridou A, Petridis I, Manolopoulos VG.
    Diabetes Res Clin Pract; 2012 Oct; 98(1):119-24. PubMed ID: 22591706
    [Abstract] [Full Text] [Related]

  • 6. Relationship between E23K (an established type II diabetes-susceptibility variant within KCNJ11), polycystic ovary syndrome and androgen levels.
    Barber TM, Bennett AJ, Gloyn AL, Groves CJ, Sovio U, Ruokonen A, Martikainen H, Pouta A, Taponen S, Weedon MN, Hartikainen AL, Wass JA, Järvelin MR, Zeggini E, Franks S, McCarthy MI.
    Eur J Hum Genet; 2007 Jun; 15(6):679-84. PubMed ID: 17342155
    [Abstract] [Full Text] [Related]

  • 7. The E23K variant in the Kir6.2 subunit of the ATP-sensitive K+ channel does not augment impaired glucose tolerance in Caribbean subjects with a family history of type 2 diabetes.
    Ezenwaka C, Kalloo R, Uhlig M, Schwenk R, Eckel J.
    J Endocrinol; 2005 Jun; 185(3):439-44. PubMed ID: 15930170
    [Abstract] [Full Text] [Related]

  • 8. Genetic variants in GCKR, GIPR, ADCY5 and VPS13C and the risk of severe sulfonylurea-induced hypoglycaemia in patients with type 2 diabetes.
    Holstein JD, Patzer O, Körner A, Stumvoll M, Kovacs P, Holstein A.
    Exp Clin Endocrinol Diabetes; 2013 Jan; 121(1):54-7. PubMed ID: 22956255
    [Abstract] [Full Text] [Related]

  • 9. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas.
    Sato R, Watanabe H, Genma R, Takeuchi M, Maekawa M, Nakamura H.
    Pharmacogenomics; 2010 Dec; 11(12):1743-50. PubMed ID: 21142918
    [Abstract] [Full Text] [Related]

  • 10. Gene-gene interactions between HNF4A and KCNJ11 in predicting Type 2 diabetes in women.
    Qi L, van Dam RM, Asselbergs FW, Hu FB.
    Diabet Med; 2007 Nov; 24(11):1187-91. PubMed ID: 17894829
    [Abstract] [Full Text] [Related]

  • 11. Search for Pharmacoepigenetic Correlations in Type 2 Diabetes Under Sulfonylurea Treatment.
    Karaglani M, Ragia G, Panagopoulou M, Balgkouranidou I, Nena E, Kolios G, Papanas N, Manolopoulos VG, Chatzaki E.
    Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):226-233. PubMed ID: 29396966
    [Abstract] [Full Text] [Related]

  • 12. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.
    Aravind SR, Ismail SB, Balamurugan R, Gupta JB, Wadhwa T, Loh SM, Suryawanshi S, Davies MJ, Girman CJ, Katzeff HL, Radican L, Engel SS, Wolthers T.
    Curr Med Res Opin; 2012 Aug; 28(8):1289-96. PubMed ID: 22738801
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation.
    Ješić MM, Ješić MD, Maglajlić S, Sajić S, Necić S.
    Diabetes Res Clin Pract; 2011 Jan; 91(1):e1-3. PubMed ID: 21056492
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas.
    Shorr RI, Ray WA, Daugherty JR, Griffin MR.
    Arch Intern Med; 2011 Jan; 157(15):1681-6. PubMed ID: 9250229
    [Abstract] [Full Text] [Related]

  • 20. Hormonal counterregulation during severe hypoglycaemia under everyday conditions in patients with type 1 and insulin-treated type 2 diabetes mellitus.
    Holstein A, Hammer C, Plaschke A, Ptak M, Kuhn J, Diekmann J, Kleesiek K, Egberts EH.
    Exp Clin Endocrinol Diabetes; 2004 Sep; 112(8):429-34. PubMed ID: 15372362
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.